Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 4291 AL 4305

Can cloud-based tools accelerate Alzheimer's disease drug discovery?

Cacabelos R, Teijido O, Carril JC.

Expert Opin Drug Discov. 2016;11(3):215-23. doi: 10.1517/17460441.2016.1141892. Epub 2016 Feb 3.

Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: protocol for a systematic review and individual patient data network meta-analysis

Veroniki AA, Straus SE, Ashoor HM, Hamid JS, Hemmelgarn BR, Holroyd-Leduc J, Majumdar SR, McAuley G, Tricco AC.

BMJ Open. 2016 Jan 13;6(1):e010251. doi: 10.1136/bmjopen-2015-010251.

Red Raspberries and Their Bioactive Polyphenols: Cardiometabolic and Neuronal Health Links

Burton-Freeman BM, Sandhu AK, Edirisinghe I.

Adv Nutr. 2016 Jan 15;7(1):44-65. doi: 10.3945/an.115.009639. Print 2016 Jan.

Positive modulators of the α7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease

Echeverria V, Yarkov A, Aliev G.

Prog Neurobiol. 2016 Sep;144:142-57. doi: 10.1016/j.pneurobio.2016.01.002. Epub 2016 Jan 12.

Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease

Ismaili L, Refouvelet B, Benchekroun M, Brogi S, Brindisi M, Gemma S, Campiani G, Filipic S, Agbaba D, Esteban G, Unzeta M, Nikolic K, Butini S, Marco-Contelles J.

Prog Neurobiol. 2017 Apr;151:4-34. doi: 10.1016/j.pneurobio.2015.12.003. Epub 2016 Jan 18.

The Emerging Therapeutic Role of NGF in Alzheimer's Disease

Xu CJ, Wang JL, Jin WL.

Neurochem Res. 2016 Jun;41(6):1211-8. doi: 10.1007/s11064-016-1829-9. Epub 2016 Jan 22.

Neuroprotective Role of Nanoparticles Against Alzheimer's Disease

Obulesu M, Jhansilakshmi M.

Curr Drug Metab. 2016;17(2):142-9. doi: 10.2174/138920021702160114160341.

Recent approaches and challenges in iPSCs: modeling and cell-based therapy of Alzheimer's disease

Csöbönyeiová M, Polák Š, Danišovič L.

Rev Neurosci. 2016 Jul 1;27(5):457-64. doi: 10.1515/revneuro-2015-0054.

Alzheimer's disease: Targeting the Cholinergic System

Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeiro FM.

Curr Neuropharmacol. 2016;14(1):101-15. doi: 10.2174/1570159x13666150716165726.

[Immunotherapy for Alzheimer's disease]

Falkentoft AC, Hasselbalch SG.

Ugeskr Laeger. 2016 Jan 18;178(3):V07150588.

Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium

Seripa D, Solfrizzi V, Imbimbo BP, Daniele A, Santamato A, Lozupone M, Zuliani G, Greco A, Logroscino G, Panza F.

Expert Rev Neurother. 2016;16(3):259-77. doi: 10.1586/14737175.2016.1140039.

Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer's Disease

Yang KC, Chen HH.

Curr Alzheimer Res. 2016;13(7):809-16. doi: 10.2174/1567205013666160129095012.

BACE1 Physiological Functions May Limit Its Use as Therapeutic Target for Alzheimer's Disease

Barão S, Moechars D, Lichtenthaler SF, De Strooper B.

Trends Neurosci. 2016 Mar;39(3):158-169. doi: 10.1016/j.tins.2016.01.003. Epub 2016 Jan 30.

Gene Therapy Strategies for Alzheimer's Disease: An Overview

Alves S, Fol R, Cartier N.

Hum Gene Ther. 2016 Feb;27(2):100-7. doi: 10.1089/hum.2016.017.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias